Feb 25, 2025 ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
Jan 29, 2025 ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
Jan 10, 2025 ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
Nov 14, 2024 ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
Nov 12, 2024 ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
Oct 30, 2024 ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
Sep 12, 2024 ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
Sep 5, 2024 ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference